Literature DB >> 12038803

Pulmonary embolism after sequential use of recombinant factor VIIa and activated prothrombin complex concentrate in a factor VIII inhibitor patient.

Stephan B Rosenfeld, Karla K Watkinson, Brad H Thompson, Donald E Macfarlane, Steven R Lentz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12038803

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN： 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  10 in total

1.  7 Procoagulators.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

2.  Emicizumab should be prescribed independent of immune tolerance induction.

Authors:  Sandra Le Quellec; Claude Negrier
Journal:  Blood Adv       Date:  2018-10-23

Review 3.  Non-catheter associated venous thrombosis in hemophilia A and B. A critical review of all reported cases.

Authors:  Antonio Girolami; Raffaella Scandellari; Ezio Zanon; Roberto Sartori; Bruno Girolami
Journal:  J Thromb Thrombolysis       Date:  2006-06       Impact factor: 2.300

Review 4.  The emerging role of recombinant-activated factor VII in neurocritical care.

Authors:  Matthew E Fewel; Paul Park
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

5.  Critical appraisal of the role of recombinant activated factor VII in the treatment of hemophilia patients with inhibitors.

Authors:  Ampaiwan Chuansumrit; Pantep Angchaisuksiri; Nongnuch Sirachainan
Journal:  J Blood Med       Date:  2010-03-30

6.  Spontaneous hemorrhage after external ventricular drain placement in the setting of low factor VII secondary to liver cirrhosis.

Authors:  Melissa Ming Jie Chua; Alvin S Das; Julie Aurore Losman; Nirav J Patel; Saef Izzy
Journal:  Surg Neurol Int       Date:  2020-11-25

Review 7.  Emerging and future therapies for hemophilia.

Authors:  Marcus E Carr; Bartholomew J Tortella
Journal:  J Blood Med       Date:  2015-09-03

Review 8.  Rivaroxaban and hemostasis in emergency care.

Authors:  Jürgen Koscielny; Edita Rutkauskaite
Journal:  Emerg Med Int       Date:  2014-02-20       Impact factor: 1.112

Review 9.  Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A.

Authors:  Sandra Le Quellec
Journal:  Drug Des Devel Ther       Date:  2020-02-03       Impact factor: 4.162

10.  Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with Inhibitors.

Authors:  Hans H Brackmann; Wolfgang Schramm; Johannes Oldenburg; Viridiana Cano; Peter L Turecek; Claude Négrier
Journal:  Hamostaseologie       Date:  2020-07-27       Impact factor: 2.145
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.